POSTED: March 24, 2014

Zocere to Present at 2014 Life Sciences & Healthcare Venture Summit in New York

 

ALBUQUERQUE, N.M., March 26, 2014 – - New Mexico-based pharmaceutical company Zocere, Inc., will be making its case to investors at the 2014 Life Sciences & Healthcare Venture Summit in New York City April 2. Zocere is developing a novel neuroprotectant treatment for ischemic stroke and other neurological disorders that shows promise as a potent “brain saving” drug when administered post stroke.

 

The Life Sciences & Healthcare Venture Summit is an annual event presented by Young Startup Ventures that connects venture capitalists, angel investors, technology transfer professionals, executives of early stage and emerging growth companies, university researchers, incubators, and service providers. Zocere is one of just 50 early stage and emerging growth companies given the opportunity to present live to some 40 leading investors. Zocere is seeking $3- to $5 million dollars to fund the commercialization of the new stroke drug.

 

Zocere’s drug candidate is a derivative of the brain-specific STEP protein ty­rosine phosphatase that when administered intravenously in rodent models, significantly reduces brain damage caused by ischemic stroke. The drug candidate is a cell-permeable, recombinant pep­tide, can cross the blood-brain barrier, resists degradation which prolongs its therapeutic effects, and can bind constitutively to its substrates.

 

Zocere’s drug candidate is significant as the last drug introduced into the stroke market was nearly 20 years ago when Genentech launched Activase®, commonly known as rt-PA. Activase is not widely used as it must be administered within a narrow window of time and also can cause deleterious side affects related to reperfusion. Zocere’s can be used in conjunction with rt-PA, increasing the time period in which the drug can be safely administered and reducing the harmful effects of reperfusion.

 

Commenting on Zocere’s participation at the Life Sciences & Healthcare Center Summit, Zocere CEO and President Wayne Laslie said it represents a unique opportunities for his company and investors. “Obviously, we are every excited about the potential of our drug candidate. We are eager to share our information and our commercialization strategy with potential investors in New York. It’s a tremendous ‘coming out party’ for a drug with such potential to transform stroke treatment and ultimately save lives.”

 

Stroke is a leading cause of death in the United States, claiming 130,000 lives each year. In 2010, the cost of stroke-related health care, medications, and missed work to the U.S. economy was $73.7 billion. Stroke is also the leading cause of long-term disability. African-Americans, Hispanics, and Native Americans are disproportionately affected by stroke.

 

About Zocere, Inc.

Headquartered in Albuquerque, New Mexico, Zocere is a startup pharmaceutical company developing injectable neuroprotectant drugs intended to combat stroke and other neurological trauma. Zocere is led by a team of seasoned pharmaceutical industry executives with extensive experience in drug commercialization. Visit www.Zocere.com.